Top Biotech Stocks To Add to Your Watchlist - July 4th

AbbVie, Thermo Fisher Scientific, Vertex Pharmaceuticals, Danaher, Moderna, Veeva Systems, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use living organisms and biological processes to develop medical therapies, diagnostics, and other life-science products. Their market value is often highly volatile, hinging on clinical trial results, regulatory approvals, and breakthroughs in research. Investors seek the outsized returns that successful drug pipelines can deliver but must accept the elevated risks of uncertain R&D outcomes. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of AbbVie stock traded down $1.25 during midday trading on Friday, hitting $189.50. The company's stock had a trading volume of 3,706,217 shares, compared to its average volume of 6,248,905. AbbVie has a 1-year low of $163.63 and a 1-year high of $218.66. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $334.73 billion, a P/E ratio of 80.64, a PEG ratio of 1.27 and a beta of 0.48. The stock has a 50-day simple moving average of $187.30 and a 200-day simple moving average of $188.36.

Read Our Latest Research Report on ABBV

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

NYSE TMO traded up $0.49 during trading on Friday, reaching $428.25. 1,359,321 shares of the company's stock were exchanged, compared to its average volume of 1,971,505. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company's fifty day simple moving average is $409.10 and its 200-day simple moving average is $480.59. The firm has a market capitalization of $161.66 billion, a PE ratio of 25.12, a P/E/G ratio of 2.27 and a beta of 0.77.

Read Our Latest Research Report on TMO

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of VRTX stock traded down $2.40 during trading on Friday, hitting $454.64. 763,957 shares of the company were exchanged, compared to its average volume of 1,418,533. The business's 50-day simple moving average is $451.62 and its 200 day simple moving average is $458.44. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88. The firm has a market capitalization of $116.75 billion, a price-to-earnings ratio of -115.98 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65.

Read Our Latest Research Report on VRTX

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR stock traded up $0.58 during midday trading on Friday, reaching $203.08. The company had a trading volume of 1,390,744 shares, compared to its average volume of 3,501,434. The company has a 50 day moving average of $195.52 and a two-hundred day moving average of $207.59. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a market capitalization of $145.33 billion, a P/E ratio of 39.43, a PEG ratio of 2.84 and a beta of 0.77.

Read Our Latest Research Report on DHR

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of NASDAQ:MRNA traded up $0.19 during midday trading on Friday, hitting $30.47. 6,972,646 shares of the stock were exchanged, compared to its average volume of 8,693,328. The business's fifty day simple moving average is $26.65 and its two-hundred day simple moving average is $31.52. Moderna has a 52-week low of $23.15 and a 52-week high of $129.39. The company has a market capitalization of $11.78 billion, a PE ratio of -3.49 and a beta of 1.84.

Read Our Latest Research Report on MRNA

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

Shares of VEEV traded down $5.39 during midday trading on Friday, reaching $277.23. 764,120 shares of the stock were exchanged, compared to its average volume of 1,159,576. The company has a market cap of $45.30 billion, a price-to-earnings ratio of 58.73, a P/E/G ratio of 2.24 and a beta of 0.98. Veeva Systems has a 12-month low of $177.41 and a 12-month high of $291.69. The firm has a 50 day simple moving average of $260.22 and a 200-day simple moving average of $236.98.

Read Our Latest Research Report on VEEV

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

NYSE COR traded up $5.06 during trading on Friday, reaching $296.23. The company's stock had a trading volume of 614,990 shares, compared to its average volume of 1,504,083. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The stock has a market capitalization of $57.42 billion, a PE ratio of 34.37, a PEG ratio of 1.44 and a beta of 0.57. The business has a 50-day moving average price of $290.91 and a 200-day moving average price of $266.76. Cencora has a 1-year low of $218.65 and a 1-year high of $309.35.

Read Our Latest Research Report on COR